Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2021
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumorsYingying Xu, Yakun Wang, Jifang Gong, et al.
The Oncologist|April 21, 2022
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and BiomarkersYakun Wang, Tianshu Liu, Gongyan Chen, et al.
Nature Medicine|June 3, 2024
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final resultsChangsong Qi, Chang Liu, Jifang Gong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2026
Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal CancerChangsong Qi, Chang Liu, Jifang Gong, et al.
Nature Medicine|May 9, 2022
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim resultsChangsong Qi, Jifang Gong, Jian Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2026
Allogeneic B7-H3-targeted CAR-Vδ1T cell therapy in advanced solid tumors: A phase I studyChang Liu, Jiarui Li, Dan Liu, et al.
Nature Medicine|July 10, 2025
A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trialChang Liu, Dan Liu, Yinghua Ji, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2021
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphomaDan Liu, Chunguang Ma, Ping Lu, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
The Lancet. Oncology|October 5, 2023
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trialXiangyu Gao, Nong Xu, Ziyu Li, et al.
Pageof 10